Coronary CTA and Plaque Analysis: From Imaging to Action

Listen in! 

The standard of care for diagnosing coronary artery disease (CAD) has changed. CCTA paired with AI-powered Plaque Analysis has emerged as a tool of choice to identify, risk stratify and stage CAD, and notably, manage and treat patients in a far more informed way. Join us to hear from three key opinion leaders as they present data and new case studies demonstrating how Plaque Analysis can help with diagnosis and management of patients with suspected CAD. One physician even shares how he has benefitted from CCTA + Plaque Analysis.

TrumpRx now online as AstraZeneca becomes second pharmaceutical company to join

TrumpRx.gov Screenshot

Screenshot from TrumpRx.gov, taken on Oct. 13, 2025.

Source

TrumpRx.gov

Details are still unclear. However, the administration—along with Pfizer and AstraZeneca, the two companies to sign on—promises the storefront will offer deeply discounted drugs directly to Americans. The deal allows the manufacturers to avoid import tariffs.